Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

NCT03679598 ·Status: COMPLETED ·Phase: PHASE2

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

NCT03385395 ·Status: WITHDRAWN ·Phase: PHASE2

Diffuse Fibrotic Lung Disease

NCT00000596 ·Status: COMPLETED ·Phase: PHASE2

A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema

NCT05466747 ·Status: WITHDRAWN ·Phase: PHASE4

Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

NCT04385836 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency

NCT03114020 ·Status: COMPLETED ·Phase: PHASE2

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

NCT00262405 ·Status: COMPLETED ·Phase: PHASE2

Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)

NCT07326592 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

A Phase 1, First-in-human Study of VX-668

NCT05727800 ·Status: COMPLETED ·Phase: PHASE1

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217 ·Status: RECRUITING ·Phase: PHASE2

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

NCT05856331 ·Status: COMPLETED ·Phase: PHASE2

Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis

NCT05722964 ·Status: COMPLETED ·Phase: PHASE2

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

NCT04589260 ·Status: TERMINATED ·Phase: PHASE1

Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis

NCT04551781 ·Status: COMPLETED ·Phase: NA

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

NCT00060801 ·Status: TERMINATED ·Phase: PHASE2

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

NCT06241560 ·Status: RECRUITING ·Phase: PHASE2

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

NCT00650091 ·Status: COMPLETED ·Phase: PHASE3

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

NCT06102083 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Trial of SHR - 1906 in Healthy Subjects

NCT04986540 ·Status: COMPLETED ·Phase: PHASE1

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

NCT01597635 ·Status: COMPLETED ·Phase: PHASE2

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

NCT04244825 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

NCT06049082 ·Status: RECRUITING ·Phase: PHASE1

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817 ·Status: COMPLETED ·Phase: PHASE2

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

NCT03422068 ·Status: COMPLETED ·Phase: PHASE1

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

NCT00261833 ·Status: COMPLETED ·Phase: PHASE4